Determination of urinary deanol ‐N‐oxide excretion profiles after ingestion of nutritional supplements containing deanol

An analytical approach employing LC –MS/MS was developed to provide first data on urinary levels of deanol-N-oxide at baseline and after the administration of deanol or meclofenoxate in humans. After a single oral dose of deanol or meclofenoxate, considerable increases of the metabolite deanol-N-oxide are observed, reaching cmax levels at 2 –5 h post-administration. Abstract2-(Dimethylamino)ethan-1-ol (Deanol) is a widely produced chemical used by both industry and consumers in a variety of applications. Meclofenoxate, a stimulant classified on the World Anti-Doping Agency Prohibited List, metabolizes into deanol and, presumably, its main metabolite deanol-N-oxide. Hence, using liquid chromatography –tandem mass spectrometry, a quantitative detection method for deanol-N-oxide in urine was developed. Subsequently, the urinary excretion of deanol-N-oxide after oral application of 130  mg of deanol was determined in six volunteers, and urine samples of a cohort of 180 male and female athletes from different sports were analyzed. In addition, urinary deanol-N-oxide was determined in an exploratory study with one volunteer ingesting 250  mg of meclofenoxate. The developed test method allowed for limits of detection and quantification for deanol-N-oxide at 0.05 and 0.15  μg/mL, respectively. Urinary deanol-N-oxide cmax levels were found between 100 and 250  μg/mL 2–5 h post-administration of 130 mg of deanol. Similarly, urine samples collected after the adminis...
Source: Drug Testing and Analysis - Category: Drugs & Pharmacology Authors: Tags: SPECIAL ISSUE ‐ RESEARCH ARTICLE Source Type: research